CellSource Co., Ltd. (JP:4880) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CellSource Co., Ltd. experienced a significant shortfall in its fiscal year results compared to earlier forecasts due to challenges in implementing synovium-derived stem cell services. The company reported a 69.3% drop in operating profit, leading to a downward revision in earnings expectations. Despite the setback, CellSource will continue its collaboration with medical institutions to develop these services.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.